BIOMAT Database Logo BIOMAT Database Logo

Production of an antigenic peptide by insulin-degrading enzyme. 2010

Nicolas Parmentier, and Vincent Stroobant, and Didier Colau, and Philippe de Diesbach, and Sandra Morel, and Jacques Chapiro, and Peter van Endert, and Benoît J Van den Eynde
Ludwig Institute for Cancer Research, Brussels Branch, Brussels, Belgium.

Most antigenic peptides presented by major histocompatibility complex (MHC) class I molecules are produced by the proteasome. Here we show that a proteasome-independent peptide derived from the human tumor protein MAGE-A3 is produced directly by insulin-degrading enzyme (IDE), a cytosolic metallopeptidase. Cytotoxic T lymphocyte recognition of tumor cells was reduced after metallopeptidase inhibition or IDE silencing. Separate inhibition of the metallopeptidase and the proteasome impaired degradation of MAGE-A3 proteins, and simultaneous inhibition of both further stabilized MAGE-A3 proteins. These results suggest that MAGE-A3 proteins are degraded along two parallel pathways that involve either the proteasome or IDE and produce different sets of antigenic peptides presented by MHC class I molecules.

UI MeSH Term Description Entries
D007339 Insulysin An enzyme the catalyzes the degradation of insulin, glucagon and other polypeptides. It is inhibited by bacitracin, chelating agents EDTA and 1,10-phenanthroline, and by thiol-blocking reagents such as N-ethylmaleimide, but not phosphoramidon. (Eur J Biochem 1994;223:1-5) EC 3.4.24.56. Insulinase,Insulin Protease,Insulin Proteinase,Insulin-Degrading Enzyme,Enzyme, Insulin-Degrading,Insulin Degrading Enzyme,Protease, Insulin,Proteinase, Insulin
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008666 Metalloendopeptidases ENDOPEPTIDASES which use a metal such as ZINC in the catalytic mechanism. Metallo-Endoproteinases,Metalloendopeptidase
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010618 Phenanthrolines Phenanthroline
D002458 Cell Fractionation Techniques to partition various components of the cell into SUBCELLULAR FRACTIONS. Cell Fractionations,Fractionation, Cell,Fractionations, Cell
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D002999 Clone Cells A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed) Clones,Cell, Clone,Cells, Clone,Clone,Clone Cell

Related Publications

Nicolas Parmentier, and Vincent Stroobant, and Didier Colau, and Philippe de Diesbach, and Sandra Morel, and Jacques Chapiro, and Peter van Endert, and Benoît J Van den Eynde
In vitro degradation of insulin-like peptide 3 by insulin-degrading enzyme.
February 2010, The protein journal,
Nicolas Parmentier, and Vincent Stroobant, and Didier Colau, and Philippe de Diesbach, and Sandra Morel, and Jacques Chapiro, and Peter van Endert, and Benoît J Van den Eynde
Stabilized β-Hairpin Peptide Inhibits Insulin Degrading Enzyme.
September 2018, Journal of medicinal chemistry,
Nicolas Parmentier, and Vincent Stroobant, and Didier Colau, and Philippe de Diesbach, and Sandra Morel, and Jacques Chapiro, and Peter van Endert, and Benoît J Van den Eynde
Identification of an insulin fragment produced by an insulin degrading enzyme, neutral thiopeptidase.
April 1987, Molecular and cellular endocrinology,
Nicolas Parmentier, and Vincent Stroobant, and Didier Colau, and Philippe de Diesbach, and Sandra Morel, and Jacques Chapiro, and Peter van Endert, and Benoît J Van den Eynde
Amyloid beta peptide processing, insulin degrading enzyme, and butyrylcholinesterase.
April 2001, Neurochemical research,
Nicolas Parmentier, and Vincent Stroobant, and Didier Colau, and Philippe de Diesbach, and Sandra Morel, and Jacques Chapiro, and Peter van Endert, and Benoît J Van den Eynde
Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme.
January 2021, Biomedicines,
Nicolas Parmentier, and Vincent Stroobant, and Didier Colau, and Philippe de Diesbach, and Sandra Morel, and Jacques Chapiro, and Peter van Endert, and Benoît J Van den Eynde
[Production of monoclonal antibodies to an insulin degrading enzyme and affinity purification of the enzyme].
June 1987, Nihon Naibunpi Gakkai zasshi,
Nicolas Parmentier, and Vincent Stroobant, and Didier Colau, and Philippe de Diesbach, and Sandra Morel, and Jacques Chapiro, and Peter van Endert, and Benoît J Van den Eynde
Insulin-degrading enzyme.
June 1996, Clinical and investigative medicine. Medecine clinique et experimentale,
Nicolas Parmentier, and Vincent Stroobant, and Didier Colau, and Philippe de Diesbach, and Sandra Morel, and Jacques Chapiro, and Peter van Endert, and Benoît J Van den Eynde
Degradation of amylin by insulin-degrading enzyme.
November 2000, The Journal of biological chemistry,
Nicolas Parmentier, and Vincent Stroobant, and Didier Colau, and Philippe de Diesbach, and Sandra Morel, and Jacques Chapiro, and Peter van Endert, and Benoît J Van den Eynde
Biological properties of an initial degradation product of insulin by insulin-degrading enzyme.
January 1989, Endocrinology,
Nicolas Parmentier, and Vincent Stroobant, and Didier Colau, and Philippe de Diesbach, and Sandra Morel, and Jacques Chapiro, and Peter van Endert, and Benoît J Van den Eynde
[Biochemical characteristics of an initial degradation product of insulin by insulin-degrading enzyme].
November 1988, Nihon Naibunpi Gakkai zasshi,
Copied contents to your clipboard!